NHMRC Industry Research Fellow Dr Isabelle Lucet, from Monash's Protein Crystallography Unit headed by Dr Jamie Rossjohn, was part of the team that determined the structure. JAK2 kinase was the driving force for many cancers and cardiovascular disorders, she said.
The research, partly funded by a $1.2 million Australian Research Council Linkage Grant, was a joint project between drug development company Cytopia Limited and the Protein Crystallography Unit.
The JAK kinases, which were first discovered by Cytopia's chief scientific officer Dr Andrew Wilks, are a well-validated drug target.
Dr Lucet said the discovery of JAK2 kinase's structure had allowed an internationally competitive structure-based drug design on JAK kinase inhibitors to begin.
"This will help the development of drugs for cancer and other disorders by assisting with the design of specific molecules."
She said the high expertise of the Monash research team, combined with the drug discovery capability of Cytopia, would undoubtedly enable more selective drug targets to be developed against diseases where the JAK kinases play a pivotal role.
Dr Lucet said the new discovery would allow the rapid growth of a portfolio of phase I therapeutics.
Details on the structure of JAK2 kinase will be published in an upcoming issue of /Blood/, the Journal of the American Society of Hematology.
*For further information contact Dr Isabelle Lucet on + 61 3 9905 3732
(office) or + 61 3 9905 3715 (laboratory) or the Media Communications
Unit, on +61 3 9905 9314.*
Ms Penny Fannin
Chief of staff
Media Communications
Marketing and Public Affairs Division
Building 65A
Monash University, Victoria, 3800
penny.fannin@adm.monash.edu.au
Tel: +61 3 9905-5828
Fax: +61 3 9905-2097
Journal
Blood